The Rothenberg Laboratory has several broad research areas and objectives, including:

Epigenetic Basis of Allergic Disease and Responses

  • Identifying epigenetic mechanisms of allergic responses

Genetic Basis of Allergic Disease

  • Identifying genes and key check points that predispose to eosinophilic and other allergic disorders

Immunopathogenesis of Allergic Inflammation

  • Elucidating the cellular and molecular processes involved in allergic responses in the gastrointestinal tract and lung
  • Developing novel models of allergic responses in vivo and in vitro
  • Testing the importance of key molecules including chemokines, cytokines and adhesion molecules in immunity

Impaired Barrier Function

  • Elucidating the role of impaired barrier function in allergic inflammation

Pathogenesis of Eosinophilic Gastrointestinal Disorders

  • Biochemically characterizing the transcriptional programs, regulating molecules and signal transduction mechanisms responsible for eosinophil development and activation
  • Translating bench discoveries into novel therapeutics that treat inflammatory diseases such as eosinophilic esophagitis (EoE) and hypereosinophilic syndromes (HES).

Precision and Predictive Medicine

  • Conducting big data (genomics, proteonomics) analyses of allergic disease with a focus on eosinophilic esophagitis (EoE)
  • Translating research findings into improved diagnostics (Learn more)

Proteases and Protease Inhibitors in Inflammation

  • Investigating the role of proteases and protease inhibitors in immunity
  • Identifying environmental factors involved in allergic diseases
  • Characterizing microbiome identity and function
  • Elucidating gene-environment interactions

Rothenberg CURED Laboratory

The mission of the laboratory, supported by the Campaign Urging Research for Eosinophilic Diseases (CURED), is to control the activity of dysregulated proteases in the esophagus as a target therapy for eosinophilic esophagitis (EoE). The laboratory comprises researchers from diverse disciplines who work together synergistically and collaborate with outside partners, including pharmaceutical companies and other academic institutions.

  • We are producing recombinant proteins and small molecules in amounts sufficient for preclinical usage.
  • We are testing the activity of candidate proteins and other chemical entities in cellular systems in vitro, as well as translational ex-vivo and in-vivo disease models.
  • We are developing novel approaches for esophageal specific delivery of drugs.